TECH [NASD]
Bio-Techne Corporation
IndexS&P 500 P/E70.46 EPS (ttm)5.12 Insider Own0.60% Shs Outstand39.27M Perf Week-6.69%
Market Cap14.46B Forward P/E35.31 EPS next Y10.23 Insider Trans-2.60% Shs Float38.95M Perf Month-0.53%
Income210.40M PEG4.70 EPS next Q1.85 Inst Own97.20% Short Float1.96% Perf Quarter4.05%
Sales1.03B P/S14.05 EPS this Y-40.40% Inst Trans-0.28% Short Ratio3.20 Perf Half Y-12.49%
Book/sh43.65 P/B8.27 EPS next Y17.20% ROA9.20% Target Price486.17 Perf Year-24.65%
Cash/sh5.77 P/C62.56 EPS next 5Y15.00% ROE12.70% 52W Range318.07 - 543.85 Perf YTD-30.20%
Dividend1.28 P/FCF56.04 EPS past 5Y4.40% ROI12.00% 52W High-31.55% Beta1.22
Dividend %0.35% Quick Ratio2.80 Sales past 5Y13.30% Gross Margin67.90% 52W Low17.04% ATR12.57
Employees2600 Current Ratio3.60 Sales Q/Q19.20% Oper. Margin25.50% RSI (14)51.85 Volatility3.59% 3.45%
OptionableYes Debt/Eq0.15 EPS Q/Q31.70% Profit Margin20.40% Rel Volume0.42 Prev Close361.12
ShortableYes LT Debt/Eq0.14 EarningsAug 04 BMO Payout23.80% Avg Volume239.35K Price372.27
Recom1.90 SMA201.22% SMA503.95% SMA200-10.02% Volume63,025 Change3.09%
Apr-25-22Downgrade Wells Fargo Equal Weight → Underweight $370
Sep-15-21Upgrade KeyBanc Capital Markets Sector Weight → Overweight $600
Mar-08-21Upgrade Stephens Equal-Weight → Overweight $380 → $425
Feb-23-21Upgrade Stifel Hold → Buy $435
Jan-25-21Reiterated The Benchmark Company Buy $320 → $410
Nov-10-20Initiated KeyBanc Capital Markets Sector Weight $340
Sep-30-20Initiated Atlantic Equities Overweight $365
Jul-15-20Downgrade Stephens Overweight → Equal-Weight
May-27-20Downgrade Stifel Buy → Hold $245 → $260
May-14-20Initiated The Benchmark Company Buy $290
Jan-08-20Resumed Stephens Overweight $250
Jan-08-20Initiated Wells Fargo Equal Weight $230
Jan-07-20Initiated Citigroup Neutral $235
Nov-15-19Initiated Stifel Buy
Jul-02-19Upgrade Janney Neutral → Buy $200 → $270
Jan-14-19Upgrade Stephens Equal-Weight → Overweight
Oct-31-18Downgrade Craig Hallum Buy → Hold
Oct-17-18Initiated Goldman Neutral $190
Jun-15-18Initiated Argus Buy $185
Jul-13-17Initiated Wells Fargo Market Perform
Aug-09-22 12:32PM  
Aug-04-22 06:30AM  
06:30AM  
06:30AM  
Jul-28-22 07:00AM  
Jul-14-22 07:00AM  
Jul-12-22 07:00AM  
Jul-06-22 07:00AM  
Jul-05-22 07:00AM  
Jun-29-22 08:38AM  
Jun-22-22 07:00AM  
Jun-15-22 08:26AM  
May-31-22 11:41AM  
May-26-22 07:00AM  
May-25-22 02:33PM  
07:00AM  
May-19-22 07:00AM  
May-12-22 07:00AM  
May-10-22 01:37PM  
07:00AM  
May-04-22 06:30AM  
06:30AM  
May-03-22 11:40AM  
May-02-22 07:00AM  
Apr-26-22 07:00AM  
Apr-13-22 07:00AM  
Apr-12-22 07:00AM  
06:35AM  
Mar-23-22 06:26PM  
Mar-17-22 08:00AM  
07:00AM  
Mar-09-22 07:00AM  
Feb-28-22 07:00AM  
Feb-22-22 04:01PM  
07:00AM  
Feb-14-22 07:00AM  
Feb-11-22 07:00AM  
Feb-10-22 07:00AM  
Feb-07-22 12:14PM  
Feb-02-22 04:18PM  
Feb-01-22 07:03AM  
06:30AM  
06:30AM  
Jan-27-22 08:00AM  
Jan-20-22 09:20AM  
Jan-18-22 07:00AM  
Jan-17-22 08:00AM  
Jan-07-22 04:01PM  
Jan-05-22 07:00AM  
07:00AM  
Jan-04-22 01:38PM  
Jan-03-22 07:00AM  
Dec-28-21 12:38AM  
Dec-27-21 09:38PM  
09:38PM  
08:38PM  
07:38PM  
07:00AM  
Dec-25-21 03:38PM  
Dec-21-21 07:00AM  
Dec-19-21 06:38AM  
Dec-17-21 11:38PM  
08:38PM  
Dec-16-21 04:38PM  
Dec-15-21 06:38PM  
Dec-14-21 11:38PM  
07:00AM  
Dec-13-21 06:38PM  
06:38PM  
04:38PM  
04:38PM  
Dec-11-21 06:38AM  
05:38AM  
03:38AM  
03:38AM  
Dec-10-21 01:38AM  
Dec-09-21 12:41PM  
Dec-08-21 06:38PM  
04:38PM  
03:38PM  
07:00AM  
Dec-07-21 04:38PM  
04:38PM  
Dec-06-21 12:41PM  
Nov-22-21 07:00AM  
Nov-09-21 07:00AM  
Nov-08-21 12:35PM  
07:00AM  
Nov-04-21 04:01PM  
01:14PM  
Nov-03-21 07:00AM  
Nov-02-21 04:01PM  
01:31PM  
06:30AM  
06:30AM  
Oct-31-21 11:17PM  
Oct-26-21 12:05PM  
Oct-22-21 07:14AM  
Oct-20-21 10:50AM  
Oct-13-21 07:00AM  
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, and diagnostics and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment provides biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment provides diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and nucleic acid analysis products for use in diagnostic or research applications, as well as instruments and process control products for hematology, blood chemistry, blood gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Novus Biologicals, Tocris Biosciences, ProteinSimple, Advanced Cell Diagnostics, and ExosomeDx brands. Bio-Techne Corporation has a clinical research collaboration with Carterra Inc. for the study of COVID-19 variants. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kummeth Charles R.CHIEF EXECUTIVE OFFICERJul 28Option Exercise108.4945,3464,919,588262,749Aug 01 06:11 PM
Kummeth Charles R.CHIEF EXECUTIVE OFFICERJul 06Option Exercise108.4950,0005,424,500248,338Jul 08 05:18 PM
HIGGINS JOHN LDirectorJun 08Option Exercise66.9060040,1405,206Jun 09 05:07 PM
HIGGINS JOHN LDirectorJun 08Sale366.09600219,6544,606Jun 09 05:07 PM
Kummeth Charles R.CHIEF EXECUTIVE OFFICERJun 07Option Exercise108.495,104553,733203,442Jun 09 05:05 PM
HIGGINS JOHN LDirectorJun 07Option Exercise66.901,00066,9005,606Jun 09 05:07 PM
HIGGINS JOHN LDirectorJun 07Sale364.311,000364,3104,606Jun 09 05:07 PM
Kummeth Charles R.CHIEF EXECUTIVE OFFICERJun 07Sale365.005,1041,862,960198,338Jun 09 05:05 PM
BAUMGARTNER ROBERT VDirectorMay 10Buy352.55300105,76510,106May 11 04:52 PM
Kelderman KimPres. Diagnostics & GenomFeb 08Option Exercise150.781,989299,9011,989Feb 10 04:31 PM
Kummeth Charles R.Chief Executive OfficerJan 28Option Exercise115.081,737199,896198,338Feb 01 04:35 PM
Kelderman KimPres. Diagnostics & GenomNov 19Option Exercise150.7850075,390500Nov 23 08:02 PM
Kelderman KimPres. Diagnostics & GenomNov 19Sale505.38500252,6890Nov 23 08:02 PM
Eansor Norman DavidPresident-Protein SciencesNov 16Option Exercise125.0579999,9152,117Nov 16 04:51 PM
Eansor Norman DavidPresident-Protein SciencesNov 12Option Exercise125.0527,1593,396,23328,477Nov 16 04:51 PM
Eansor Norman DavidPresident-Protein SciencesNov 12Sale504.0027,15913,688,1931,318Nov 16 04:51 PM
Hippel JamesChief Financial OfficerNov 02Option Exercise125.0520025,01010,955Nov 03 05:29 PM
Hippel JamesChief Financial OfficerNov 02Sale525.10200105,02010,755Nov 03 05:29 PM
Hippel JamesChief Financial OfficerNov 01Option Exercise125.058,8221,103,19119,577Nov 03 05:29 PM
Hippel JamesChief Financial OfficerNov 01Sale526.528,8224,644,97010,755Nov 03 05:29 PM
Hippel JamesChief Financial OfficerOct 29Option Exercise125.0566282,78311,417Nov 01 04:36 PM
Hippel JamesChief Financial OfficerOct 29Sale525.23662347,70410,755Nov 01 04:36 PM
Hippel JamesChief Financial OfficerOct 28Sale525.1810052,51810,755Nov 01 04:36 PM
Kelderman KimPres. Diagnostics & GenomSep 22Sale529.04822434,8710Sep 24 04:30 PM
STEER RANDOLPH CDirectorSep 07Option Exercise89.588,000716,68013,112Sep 09 04:26 PM
STEER RANDOLPH CDirectorSep 07Sale509.988,0004,079,8235,112Sep 09 04:26 PM
Furlow Brenda S.SVP - General CounselSep 02Option Exercise125.056,871859,21914,491Sep 07 04:58 PM
Hippel JamesChief Financial OfficerSep 02Option Exercise106.5910,0001,065,90020,855Sep 07 04:59 PM
Kummeth Charles R.Chief Executive OfficerSep 02Option Exercise108.4973,4927,973,147238,606Sep 07 05:00 PM
Hippel JamesChief Financial OfficerSep 02Sale507.2210,0005,072,16510,855Sep 07 04:59 PM
Furlow Brenda S.SVP - General CounselSep 02Sale509.946,8713,503,7647,620Sep 07 04:58 PM
Furlow Brenda S.SVP - General CounselAug 31Option Exercise125.055,000625,25012,620Sep 02 04:48 PM
Furlow Brenda S.SVP - General CounselAug 31Sale505.665,0002,528,3117,620Sep 02 04:48 PM
Eansor Norman DavidPresident-Protein SciencesAug 31Sale503.071,538773,7281,318Sep 02 04:49 PM
BAUMGARTNER ROBERT VDirectorAug 23Option Exercise87.394,000349,56013,612Aug 25 04:42 PM
Nusse RoelandDirectorAug 23Option Exercise70.354,000281,40010,765Aug 25 05:13 PM
Nusse RoelandDirectorAug 23Sale481.524,0001,926,0656,765Aug 25 05:13 PM
BAUMGARTNER ROBERT VDirectorAug 23Sale485.554,0001,942,1839,612Aug 25 04:42 PM
Furlow Brenda S.SVP - General CounselAug 19Option Exercise109.994,337477,03011,158Aug 23 04:15 PM
Furlow Brenda S.SVP - General CounselAug 19Sale473.953,5381,676,8497,620Aug 23 04:15 PM
Kummeth Charles R.Chief Executive OfficerAug 11Option Exercise108.4992199,919165,114Aug 13 04:03 PM